AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results

Key Takeaways The study showed Pyrukynd met its hemoglobin endpoint but missed its goal of reducing pain crises.AGIO reported mixed secondary results, with gains in hemoglobin and bilirubin but no fatigue improvement.Agios plans a regulatory filing in early 2026, citing clearer benefits in hemoglobin responders.Shares of Agios Pharmaceuticals (AGIO) tanked about 51% on Wednesday after it reported mixed top-line results from the phase III RISE UP study, which evaluated orally administered Pyrukynd (mitapivat ...